Comparative Pharmacology
Head-to-head clinical analysis: MICRODERM versus TAZORAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRODERM versus TAZORAC.
MICRODERM vs TAZORAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
Apply a pea-sized amount to affected areas once daily in the evening. Tazorac is available as a 0.05% or 0.1% gel or cream. For plaque psoriasis, the 0.1% gel is typically used. For acne, the 0.1% cream or gel is started, then decreased to 0.05% if irritation occurs.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Terminal elimination half-life of tazarotenic acid is approximately 18 hours (range 7-30 hours) after topical application, allowing once-daily dosing; systemic exposure is low due to extensive protein binding and slow clearance.
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
Primarily fecal: approximately 60-70% eliminated in feces (as metabolites), renal excretion accounts for <10% as unchanged drug and metabolites, with <1% as unchanged tazarotenic acid.
Category C
Category C
Topical Retinoid
Topical Retinoid